Annals of Surgical Oncology

, Volume 19, Issue 2, pp 402–408 | Cite as

Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis

  • Pierluigi Pilati
  • Simone Mocellin
  • Loris Bertazza
  • Francesca Galdi
  • Marta Briarava
  • Enzo Mammano
  • Emanuela Tessari
  • Giorgio Zavagno
  • Donato Nitti
Colorectal Cancer

Abstract

Background

Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery.

Methods

We considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model.

Results

Univariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9–3.7, P < 0.0001; and hazard ratio 2.1, 95% CI 1.4–3.2, P < 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9–3.6, P < 0.0001), indicating that this biomarker can independently predict the survival of these patients.

Conclusions

CD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments.

References

  1. 1.
    Primrose JN. Surgery for colorectal liver metastases. Br J Cancer. 2010;102:1313–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Lise M, Mocellin S, Pilati P, Nitti D. Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. Front Biosci. 2005;10:3042–57.PubMedCrossRefGoogle Scholar
  3. 3.
    Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010;22:364–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Mayo SC, Pawlik TM. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol. 2009;3:131–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28:2300–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev. 2006;(4):CD003770.Google Scholar
  7. 7.
    Ruo L, DeMatteo RP, Blumgart LH. The role of adjuvant therapy after liver resection for colorectal cancer metastases. Clin Colorectal Cancer. 2001;1:154–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2010;9:13–25.Google Scholar
  9. 9.
    Mocellin S, Lise M, Nitti D. Targeted therapy for colorectal cancer: mapping the way. Trends Mol Med. 2005;11:327–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138:1714–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Peach G, Kim C, Zacharakis E, et al. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010;102:1327–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Allen JE, El-Deiry WS. Circulating tumor cells and colorectal cancer. Curr Colorectal Cancer Rep. 2010;6:212–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398–406.PubMedCrossRefGoogle Scholar
  14. 14.
    Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist. 2009;14:1070–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the “leukemic phase” of solid cancers. Trends Mol Med. 2006;12:130–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Mocellin S, Hoon D, Ambrosi A, et al. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006;12:4605–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Bertazza L, Mocellin S, Marchet A, et al. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med. 2009;7:111.PubMedCrossRefGoogle Scholar
  19. 19.
    Mocellin S, Del Fiore P, Guarnieri L, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004;111:741–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Grambsch TM, Therneau M. Modelling survival data. New York: Springer, 2000.Google Scholar
  22. 22.
    Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Harel O, Zhou XH. Multiple imputation: review of theory, implementation and software. Stat Med. 2007;26:3057–77.PubMedCrossRefGoogle Scholar
  25. 25.
    Hebbar M, Pruvot FR, Romano O, et al. Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer. Cancer Treat Rev. 2009;35:668–75.PubMedCrossRefGoogle Scholar
  26. 26.
    National Comprehensive Cancer Network. Colon cancer. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. http://www.nccn.org/.
  27. 27.
    Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489–99.PubMedCrossRefGoogle Scholar
  28. 28.
    Weiss L. Metastatic inefficiency. Adv Cancer Res. 1990;54:159–211.PubMedCrossRefGoogle Scholar
  29. 29.
    Yu M, Stott S, Toner M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2010;192:373–82.CrossRefGoogle Scholar
  30. 30.
    Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2011;5:12517.Google Scholar
  31. 31.
    Riethdorf S, Pantel K. Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci. 2010;1210:66–77.PubMedCrossRefGoogle Scholar
  32. 32.
    Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.PubMedCrossRefGoogle Scholar
  33. 33.
    O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:90–100.PubMedCrossRefGoogle Scholar
  35. 35.
    Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2011;138:2151–62.CrossRefGoogle Scholar
  36. 36.
    Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133 metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111–20.PubMedGoogle Scholar
  37. 37.
    Nakamura K, Iinuma H, Aoyagi Y, et al. Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery. Oncology. 2011;78:309–15.CrossRefGoogle Scholar
  38. 38.
    Artells R, Moreno I, Diaz T, et al. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer. 2011;46:642–9.CrossRefGoogle Scholar
  39. 39.
    Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44 s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2011;103:382–90.CrossRefGoogle Scholar
  41. 41.
    Gazzaniga P, Gradilone A, Petracca A, et al. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med. 2011;14:2073–7.CrossRefGoogle Scholar
  42. 42.
    Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer. 2007;110:534–42.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Pierluigi Pilati
    • 1
  • Simone Mocellin
    • 1
  • Loris Bertazza
    • 1
    • 2
  • Francesca Galdi
    • 1
  • Marta Briarava
    • 1
  • Enzo Mammano
    • 1
  • Emanuela Tessari
    • 1
  • Giorgio Zavagno
    • 1
  • Donato Nitti
    • 1
  1. 1.Surgery Branch, Department of Oncological and Surgical SciencesUniversity of PadovaPadovaItaly
  2. 2.Istituto Oncologico Veneto (IOV-IRCCS)PadovaItaly

Personalised recommendations